home   genetic news   bioinformatics   biotechnology   literature   journals   ethics   positions   events   sitemap
  HUM-MOLGEN -> Events -> Meetings and Conferences  

3rd Diabetes Summit on April 29 - April 30, 2013 in Boston, MA

  January 11, 2013  

GTC’s 3rd Diabetes Summit on April 29 - April 30, 2013 in Boston, MA is the only diabetes conference that provides delegates the opportunity to facilitate discussions and collaborations among affiliations (industry, academia, government) that can lead to the advancement of therapeutics and development of drugs/treatments for diabetes, and hopefully one day a cure. As well as providing updated educational research on various novel targets, therapeutics, developments, and technologies; regulatory guidance; case studies on successful and/or unsuccessful clinical trials; and other relevant insights that can help delegates advance their own research and therapeutics.

We look forward to seeing you at the conference!


Conference Date: April 29-30, 2013

Organized by: GTC
Invited Speakers:
Riccardo Perfetti
Vice President, Global Medical Affairs
Allan Ertmann Karlsen
Corporate Vice President
Diabetes Biology & 
Research Institute
Diabetes Research Unit
Novo Nordisk A/S
G. Steven Burrill
    Burrill & Company   
Ed Damiano
Associate Professor
 Biomedical Engineering

Boston University

Mostafa Analoui
Head; Healthcare and Life Sciences
The Livingston Group

Barbara Corkey
Vice Chair for Research
Boston University School of Medicine

John Mc Elroy
President and CSO

Jenrin Discovery

Kurt Graves
Executive Chairman & CEO
Intarcia Therapeutics

Bart Henderson
President & Founder

George Kunos
Scientific Director

Tomas Landh
Director, Stragegy and Sourcing, Diabetes Research Unit

Randall Nelson
Research Professor, Molecular Biomarkers Lab
Arizona State University

Karen Segal
Senior Vice President
Diabetes and Metabolic Diseases
Meso Blast

Lauren Shearman
Strategic Licensing & Acquisitions Lead
Diabetes & Endocrinology
External Scientific Affairs
Worldwide Licensing & Acquisitions

Peter Stein
Head; Development Metabolism
Janssen R&D US

Solomon Steiner
Managing Director
Steiner Ventures

Jim Wang
VP, Cardiovascular and Metabolic Diseases Research
Crown Bioscience (Taicang) Inc.

Advisory Board Members Helping to Organize the Event

Paul Burton
Vice President, Franchise Medical Leader
Johnson and Johnson Pharmaceutical Research Division

Richard Caroddo
Business Development Executive

Steven Cohen
Senior Director
Daiichi Sankyo

Lisa Jansa
Chief Executive Officer
Exsulin Corporation

Allan Ertmann Karlsen
Vice President

Urban Kiernan
Senior Scientist
Thermo Fischer

Christopher Kiritsy
President and Chief Executive Officer, Co-Founder
Arisaph Pharmaceuticals

Tomas Landh
Director, Strategy and Sourcing, Diabetes Research Unit
Novo Nordisk

James Lenhard
Research Fellow
Johnson & Johnson

Yin Liang
Head of In Vivo Section
Johnson & Johnson

Jeffrey Pfefferkorn
Senior Principal Scientist

David Warnock
School of Medicine at the University of Alabama at Birmingham

Jim Wang
VP, Cardiovascular and Metabolic Diseases Research
Crown Bioscience (Taicang)
Deadline for Abstracts: 2013/4/29
Registration: https://www.gtcbio.com/index.php?option=com_register&cn=Diabetes%20Summit%202013&cid=115
E-mail: Scott.Mccue@gtcbio.com
home   genetic news   bioinformatics   biotechnology   literature   journals   ethics   positions   events   sitemap

Generated by meetings and positions 5.0 by Kai Garlipp
WWW: Kai Garlipp, Frank S. Zollmann.
7.0 © 1995- HUM-MOLGEN. All rights reserved. Liability, Copyright and Imprint.